Syrian Arab RepublicTuberculosis profile
Population  2016 18 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.023 (0.022–0.023) 0.12 (0.12–0.13)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0 (0–0.01)
Incidence  (includes HIV+TB) 3.8 (2.9–4.8) 21 (16–26)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.02 (0.01–0.03)
Incidence (MDR/RR-TB)** 0.37 (0.23–0.51) 2 (1.2–2.8)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.2 (0.15–0.25) 1.2 (0.93–1.6) 1.4 (1.1–1.8)
Males 0.22 (0.17–0.28) 2.2 (1.6–2.7) 2.4 (1.8–3)
Total 0.42 (0.31–0.52) 3.4 (2.6–4.3) 3.8 (2.9–4.8)
TB case notifications, 2016  
Total cases notified 3 154
Total new and relapse 3 064
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 1%
          - % pulmonary 53%
          - % bacteriologically confirmed among pulmonary 76%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.01 (0–0.01)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 1 2%
          - on antiretroviral therapy 1 100%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  160
(110–210)
Estimated % of TB cases with MDR/RR-TB 8% (4.9–11) 24% (16–35)  
% notified tested for rifampicin resistance 0% 47% 82
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 23, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 14, XDR-TB: 9
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 91% 2 908
Previously treated cases, excluding relapse, registered in 2015 48% 84
HIV-positive TB cases registered in 2015   0
MDR/RR-TB cases started on second-line treatment in 2014 42% 12
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
15% (14–17)
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-23 Data: www.who.int/tb/data